Mechanisms of echinocandin antifungal drug resistance

Positions and Numbers ofFKSMutations in Candida albicans Selectively InfluenceIn VitroandIn VivoSusceptibilities to Echinocandin Treatment

(2014) M. Lackner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates

(2014) Gregory A. Eschenauer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin

(2014) Fernando César Bizerra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance

(2014) Cau D. Pham et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia

(2014) N. D. Beyda et al.   CLINICAL INFECTIOUS DISEASES

Systemic Antifungal Prophylaxis After Hematopoietic Stem Cell Transplantation: A Meta-Analysis

(2014) Panayiotis D. Ziakas et al.   CLINICAL THERAPEUTICS

Echinocandin resistance

(2014) Maiken C. Arendrup et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.

(2014) Maiken C. Arendrup et al.   DRUG RESISTANCE UPDATES

Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?

(2014) A. Fekkar et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Candida glabrata Intra-Abdominal Candidiasis Is Characterized by Persistence within the Peritoneal Cavity and Abscesses

(2014) Shaoji Cheng et al.   INFECTION AND IMMUNITY

Development of echinocandin-resistantCandida albicanscandidemia following brief prophylactic exposure to micafungin therapy

(2014) M.A. Ruggero et al.   Transplant Infectious Disease

A Tetraploid Intermediate Precedes Aneuploid Formation in Yeasts Exposed to Fluconazole

(2014) Benjamin D. Harrison et al.   PLOS BIOLOGY

Role of Matrix β-1,3 Glucan in Antifungal Resistance of Non-albicans Candida Biofilms

(2013) K. F. Mitchell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Species-Specific and Drug-Specific Differences in Susceptibility of Candida Biofilms to Echinocandins: Characterization of Less Common Bloodstream Isolates

(2013) Maria Simitsopoulou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Frequency offksMutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates

(2013) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter Study of Anidulafungin and Micafungin MIC Distributions and Epidemiological Cutoff Values for Eight Candida Species and the CLSI M27-A3 Broth Microdilution Method

(2013) M. A. Pfaller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid Emergence of Echinocandin Resistance in Candida glabrata Resulting in Clinical and Microbiologic Failure

(2013) James S. Lewis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid Emergence of Echinocandin Resistance during Candida kefyr Fungemia Treatment with Caspofungin

(2013) A. Fekkar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade

(2013) A. M. Tortorano et al.   INFECTION

Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Transcriptional Activation of Heat Shock Protein 90 Mediated Via a Proximal Promoter Region as Trigger of Caspofungin Resistance in Aspergillus fumigatus

(2013) Frédéric Lamoth et al.   JOURNAL OF INFECTIOUS DISEASES

Newer Antifungal Agents for Fungal Infection Prevention During Hematopoietic Cell Transplantation: A Meta-Analysis

(2013) S.-X. Xu et al.   TRANSPLANTATION PROCEEDINGS

Regulatory Role of Glycerol in Candida albicans Biofilm Formation

(2013) J. V. Desai et al.   mBio

Fks1 and Fks2 Are Functionally Redundant but Differentially Regulated in Candida glabrata: Implications for Echinocandin Resistance

(2012) Santosh K. Katiyar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Presence of anFKSMutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata

(2012) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stepwise Development of a Homozygous S80P Substitution in Fks1p, Conferring Echinocandin Resistance in Candida tropicalis

(2012) Rasmus Hare Jensen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DifferentialIn VivoActivities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and withoutFKSResistance Mutations

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin

(2012) Louise A. Walker et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis

(2012) Michaela Döring et al.   BMC INFECTIOUS DISEASES

Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011

(2012) A. A. Cleveland et al.   CLINICAL INFECTIOUS DISEASES

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

(2012) W.W. Hope et al.   CLINICAL MICROBIOLOGY AND INFECTION

Micafungin

(2012) Lesley J. Scott   DRUGS

Topological and Mutational Analysis of Saccharomyces cerevisiae Fks1

(2012) Michael E. Johnson et al.   EUKARYOTIC CELL

Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata

(2012) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

CRS-MIS inCandida glabrata: sphingolipids modulate echinocandin-Fks interaction

(2012) Kelley R. Healey et al.   MOLECULAR MICROBIOLOGY

The Hsp90 Co-Chaperone Sgt1 Governs Candida albicans Morphogenesis and Drug Resistance

(2012) Rebecca S. Shapiro et al.   PLoS One

Hidden Killers: Human Fungal Infections

(2012) G. D. Brown et al.   Science Translational Medicine

Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata

(2012) Sheena D. Singh-Babak et al.   PLoS Pathogens

Prior Caspofungin Exposure in Patients with Hematological Malignancies Is a Risk Factor for Subsequent Fungemia Due to Decreased Susceptibility in Candida spp.: a Case-Control Study in Paris, France

(2011) Elodie Blanchard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Candida glabrataMutants Demonstrating Paradoxical Reduced Caspofungin Susceptibility but Increased Micafungin Susceptibility

(2011) Kelley R. Healey et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans

(2011) Nathan P. Wiederhold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin

(2011) J. L. Slater et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Fks Hot Spot for Acquired Echinocandin Resistance inSaccharomyces cerevisiaeand Its Contribution to Intrinsic Resistance ofScedosporiumSpecies

(2011) Michael E. Johnson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin ResistanceIn Vivo

(2011) Keunsook K. Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Current perspectives on echinocandin class drugs

(2011) David S Perlin   Future Microbiology

Regulation of Cell Wall Biogenesis inSaccharomyces cerevisiae: The Cell Wall Integrity Signaling Pathway

(2011) David E. Levin   GENETICS

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009)

(2011) Michael A. Pfaller et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy

(2011) Susan J. Howard et al.   JOURNAL OF INFECTIOUS DISEASES

Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance

(2011) Ronen Ben-Ami et al.   JOURNAL OF INFECTIOUS DISEASES

Aneuploidy Drives Genomic Instability in Yeast

(2011) J. M. Sheltzer et al.   SCIENCE

Importance of Candida–bacterial polymicrobial biofilms in disease

(2011) Melphine M. Harriott et al.   TRENDS IN MICROBIOLOGY

Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains

(2010) M. Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients

(2010) Olivier Lortholary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species

(2010) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009)

(2010) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Echinocandin Antifungal Drugs in Fungal Infections

(2010) Sharon C.-A. Chen et al.   DRUGS

Breakthrough Invasive Candidiasis in Patients on Micafungin

(2010) C. D. Pfeiffer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)

(2010) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Comparative Efficacy of Echinocandins and Nonechinocandins for the Treatment ofCandida parapsilosisInfections: A Meta-analysis

(2010) Pramodini B Kale-Pradhan et al.   PHARMACOTHERAPY

PKC Signaling Regulates Drug Resistance of the Fungal Pathogen Candida albicans via Circuitry Comprised of Mkc1, Calcineurin, and Hsp90

(2010) Shantelle L. LaFayette et al.   PLoS Pathogens

Role for Fks1 in the Intrinsic Echinocandin Resistance of Fusarium solani as Evidenced by Hybrid Expression in Saccharomyces cerevisiae

(2009) S. K. Katiyar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Biofilm Formation and Effect of Caspofungin on Biofilm Structure of Candida Species Bloodstream Isolates

(2009) J. A. G. Ferreira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit

(2009) M.A. Ghannoum et al.   CLINICAL MICROBIOLOGY AND INFECTION

Fungal echinocandin resistance

(2009) Louise A. Walker et al.   FUNGAL GENETICS AND BIOLOGY

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins andCandidaspp.

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease

(2009) Leah E. Cowen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hsp90 Orchestrates Stress Response Signaling Governing Fungal Drug Resistance

(2009) Leah E. Cowen   PLoS Pathogens

Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin

(2009) Sheena D. Singh et al.   PLoS Pathogens

Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

(2008) J. D. Cleary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans

(2008) N. P. Wiederhold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection

(2008) G. R. Thompson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance

(2008) Leah E. Cowen et al.   EUKARYOTIC CELL

Functional analysis of Candida albicans GPI-anchored proteins: Roles in cell wall integrity and caspofungin sensitivity

(2008) Armêl Plaine et al.   FUNGAL GENETICS AND BIOLOGY

Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy

(2008) N. Kabbara et al.   HAEMATOLOGICA

Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins

(2008) Louise A. Walker et al.   PLoS Pathogens

Increasing incidence of Candida parapsilosis candidemia with caspofungin usage

(2007) Graeme N. Forrest et al.   JOURNAL OF INFECTION